Funded Project Details - FY2021
|Title:|| Optimizing anti-tumor immunity for maximal therapeutic efficacy in Colorectal Cancer|
Jonathan B Mitchem
|Congressional District Code:
||Biomedical Laboratory R&D
|| October 2018 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Project Summary: Colorectal cancer (CRC) accounts for nearly 10% of all cancer diagnoses in the VA system1. Additionally, the VA system treats 3% of the total number of US cases of CRC and 6% of all US cases in males2. The immune response to CRC is critical to therapeutic response and survival. Cytotoxic T cells (CTL) are the end mediators of the anti-tumor response. As expected, tumor associated CTL are also associated with treatment response and survival in CRC. In our murine model of colorect...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.